title: The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
abstract: Type 2 diabetes mellitus (T2DM) is primarily a self-managed disease in which self-care behaviors play an important role in achieving optimal outcomes. Because self-care does not result in immediate tangible or noticeable benefits, adherence to such a regimen can be confusing, difficult, and frustrating. People are more likely to adhere to treatment regimens that offer benefits from the patient perspective, such as convenience, avoidance of hypoglycemic episodes, and weight loss, compared with regimens that do not. In this study, we explored the impact of the average weight loss amount demonstrated with canagliflozin treatment on improvement in 3 patient-relevant outcomes that have been linked to performance of healthy behaviors and better outcomes in T2DM: weight-related quality of life, as measured by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, and satisfaction with physical health and emotional health, as measured by the Current Health Satisfaction Questionnaire (CHES-Q), using data from a previously reported study. Weight loss of an amount demonstrated in clinical trials of canagliflozin was associated with improvements in weight-related quality of life and satisfaction with physical and emotional health, concepts shown to be important to the persistent and consistent performance of healthy behaviors.
authors.affiliation: Janssen Global Services, LLC, Raritan, NJ. straina@its.jnj.com.
authors.forename: Shana
authors.initials: S
authors.lastname: Traina
authors.forename: Robert
authors.initials: R
authors.lastname: Guthrie
authors.forename: April
authors.initials: A
authors.lastname: Slee
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001835:Body Weight; D000068896:Canagliflozin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005960:Glucosides / Q000008:administration & dosage / Q000627:therapeutic use*; D006442:Glycated Hemoglobin; D015438:Health Behavior; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010549:Personal Satisfaction; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D020377:Self Efficacy; D012737:Sex Factors; D012725:Sexual Behavior; D000068900:Sitagliptin Phosphate; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D000068896:Canagliflozin; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D013876:Thiophenes; D014230:Triazoles